Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

16919D702NC00001-NCT07221253OpenPhase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)D702NC00001NCT07221253IndustrialAdultTreatmentIIIOtherCoffman, KelleyGeorgetown University Medical Center : Princess Jones; Lombardi Comprehensive Cancer Center : Princess JonesGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS14509Princess JonesPrincess Jonespaj24@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>